• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating.快速药物洗脱交联脂肪酸冠状动脉支架涂层的持续疗效和动脉药物保留
Ann Biomed Eng. 2016 Feb;44(2):276-86. doi: 10.1007/s10439-015-1435-z. Epub 2015 Aug 28.
2
Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.生物可吸收聚合物涂层西罗莫司洗脱支架在人体冠状动脉中的有效性和安全性。
Catheter Cardiovasc Interv. 2007 Feb 1;69(2):198-202. doi: 10.1002/ccd.20926.
3
Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating.新型生物可吸收的水杨酸基聚合物作为药物洗脱支架涂层。
Catheter Cardiovasc Interv. 2008 Aug 1;72(2):186-94. doi: 10.1002/ccd.21607.
4
Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.一种新型药物洗脱支架系统对新生内膜形成的抑制作用,该系统可实现剂量可调、多次及原位支架涂层。
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):748-53. doi: 10.1161/01.ATV.0000157579.52566.ee. Epub 2005 Jan 27.
5
A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus.一种新型药物洗脱支架,喷涂有多层胶原蛋白和西罗莫司。
J Control Release. 2005 Nov 2;108(1):178-89. doi: 10.1016/j.jconrel.2005.07.022. Epub 2005 Sep 12.
6
Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo.药物从磷酸胆碱聚合物涂层冠状动脉支架上的负载和洗脱不会影响该涂层在体内的长期稳定性。
Biomed Mater Eng. 2004;14(4):355-70.
7
Vascular response and mechanical integrity of the new biodegradable polymer coated sirolimus-eluting PROLIM stent implanted in porcine coronary arteries.新型可生物降解聚合物涂层西罗莫司洗脱 PROLIM 支架在猪冠状动脉中的血管反应和机械完整性。
Kardiol Pol. 2012;70(7):703-11.
8
Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.用于基于支架的局部药物递送的雷帕霉素类似物。依维莫司和他克莫司洗脱支架。
Herz. 2004 Mar;29(2):162-6. doi: 10.1007/s00059-004-2556-6.
9
Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.降低从非聚合羟基磷灰石涂层冠状动脉支架释放的西罗莫司剂量,可减少延迟愈合的迹象。
JACC Cardiovasc Interv. 2009 Apr;2(4):284-90. doi: 10.1016/j.jcin.2008.12.012.
10
[Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].[德国西罗莫司洗脱冠状动脉支架“实际使用”中的安全性及当前适应证。德国前瞻性多中心西罗莫司洗脱支架注册研究结果]
Herz. 2004 Mar;29(2):181-6. doi: 10.1007/s00059-004-2560-x.

引用本文的文献

1
Endovascular Drug Delivery.血管内药物递送
Life (Basel). 2024 Mar 28;14(4):451. doi: 10.3390/life14040451.
2
Evolution of drug-eluting biomedical implants for sustained drug delivery.药物洗脱生物医学植入物的演变用于持续药物输送。
Eur J Pharm Biopharm. 2021 Feb;159:21-35. doi: 10.1016/j.ejpb.2020.12.005. Epub 2020 Dec 16.
3
In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives.体外 Cas9 辅助编辑模块化聚酮合酶基因以生产所需的天然产物衍生物。
Nat Commun. 2020 Aug 11;11(1):4022. doi: 10.1038/s41467-020-17769-2.
4
Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics.将紫杉醇涂层球囊提升到一个新的水平:预测涂层溶解动力学、组织保留和给药动力学。
J Control Release. 2019 Sep 28;310:94-102. doi: 10.1016/j.jconrel.2019.08.019. Epub 2019 Aug 17.
5
Endovascular Drug Delivery and Drug Elution Systems: First Principles.血管内药物递送与药物洗脱系统:基本原理
Interv Cardiol Clin. 2016 Jul;5(3):307-320. doi: 10.1016/j.iccl.2016.02.007. Epub 2016 Jun 21.

本文引用的文献

1
The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study.SYNERGY生物可降解聚合物依维莫司洗脱冠状动脉支架:猪血管相容性及聚合物安全性研究。
Catheter Cardiovasc Interv. 2015 Nov 15;86(6):E247-57. doi: 10.1002/ccd.25993. Epub 2015 May 23.
2
Current concepts on cardiovascular stent devices.心血管支架装置的当前概念。
Mini Rev Med Chem. 2014;14(6):505-36. doi: 10.2174/1389557514666140530093620.
3
Stent elution rate determines drug deposition and receptor-mediated effects.支架洗脱率决定药物沉积和受体介导的作用。
J Control Release. 2012 Aug 10;161(3):918-26. doi: 10.1016/j.jconrel.2012.05.039. Epub 2012 May 26.
4
Design principles and performance of bioresorbable polymeric vascular scaffolds.生物可吸收聚合物血管支架的设计原则和性能。
EuroIntervention. 2009 Dec 15;5 Suppl F:F15-22. doi: 10.4244/EIJV5IFA3.
5
Assessment of material by-product fate from bioresorbable vascular scaffolds.生物可吸收血管支架中材料副产物归宿的评估。
Ann Biomed Eng. 2012 Apr;40(4):955-65. doi: 10.1007/s10439-011-0445-8. Epub 2011 Oct 26.
6
A review of the composition, characteristics, and effectiveness of barrier mesh prostheses utilized for laparoscopic ventral hernia repair.用于腹腔镜腹疝修补的屏障网假体的组成、特性和有效性的综述。
Surg Endosc. 2012 Feb;26(2):566-75. doi: 10.1007/s00464-011-1899-3. Epub 2011 Sep 5.
7
Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions).药物释放动力学对长病变患者植入不同依维莫司洗脱支架后血管反应的影响:LongOCT 研究(长病变中的光学相干断层扫描)。
JACC Cardiovasc Interv. 2011 Jul;4(7):778-85. doi: 10.1016/j.jcin.2011.04.007.
8
Structural identification of SAR-943 metabolites generated by human liver microsomes in vitro using mass spectrometry in combination with analysis of fragmentation patterns.采用质谱联用技术结合碎片分析对人肝微粒体体外生成的 SAR-943 代谢物进行结构鉴定。
J Mass Spectrom. 2011 Jul;46(7):615-24. doi: 10.1002/jms.1930.
9
Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings.在高风险介入治疗环境中,支架的早期血栓形成是由支架设计和部署驱动的,并受到聚合物药物涂层的保护。
Circulation. 2011 Apr 5;123(13):1400-9. doi: 10.1161/CIRCULATIONAHA.110.003210. Epub 2011 Mar 21.
10
Polymers for drug eluting stents.药物洗脱支架用聚合物。
Curr Pharm Des. 2010;16(36):3978-88. doi: 10.2174/138161210794454897.

快速药物洗脱交联脂肪酸冠状动脉支架涂层的持续疗效和动脉药物保留

Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating.

作者信息

Artzi Natalie, Tzafriri Abraham R, Faucher Keith M, Moodie Geoffrey, Albergo Theresa, Conroy Suzanne, Corbeil Scott, Martakos Paul, Virmani Renu, Edelman Elazer R

机构信息

Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.

Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Ann Biomed Eng. 2016 Feb;44(2):276-86. doi: 10.1007/s10439-015-1435-z. Epub 2015 Aug 28.

DOI:10.1007/s10439-015-1435-z
PMID:26314990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4767594/
Abstract

The long held assumption that sustained drug elution from stent coatings over weeks to months is imperative for clinical efficacy has limited the choice for stent coating materials. We developed and evaluated an omega-3 fatty acid (O3FA) based stent coating that is 85% absorbed and elutes 97% of its Sirolimus analog (Corolimus) load within 8d of implantation. O3FA coated stents sustained drug levels in porcine coronary arteries similarly to those achieved by slow-eluting durable coated Cypher Select Plus Stents and with significantly lower levels of granuloma formation and luminal stenosis. Computational modeling confirmed that diffusion and binding constants of Corolimus and Sirolimus are identical and explained that the sustained retention of Corolimus was facilitated by binding to high affinity intracellular receptors (FKBP12). First in man outcomes were positive-unlike Cypher stents where late lumen loss drops over 6 month, there was a stable effect without diminution in the presence of O3FA. These results speak to a new paradigm whereby the safety of drug eluting stents can be optimized through the use of resorbable biocompatible coating materials with resorption kinetics that coincide with the dissociation and tissue elimination of receptor-bound drug.

摘要

长期以来一直认为,支架涂层在数周甚至数月内持续释放药物对于临床疗效至关重要,这限制了支架涂层材料的选择。我们研发并评估了一种基于ω-3脂肪酸(O3FA)的支架涂层,该涂层85%被吸收,在植入后8天内可洗脱其97%的西罗莫司类似物(科罗莫司)负载量。O3FA涂层支架在猪冠状动脉中维持的药物水平与缓释耐用涂层Cypher Select Plus支架所达到的水平相似,且肉芽肿形成和管腔狭窄水平显著更低。计算模型证实,科罗莫司和西罗莫司的扩散和结合常数相同,并解释了科罗莫司的持续保留是通过与高亲和力细胞内受体(FKBP12)结合来实现的。首例人体试验结果是阳性的——与Cypher支架不同,Cypher支架的晚期管腔丢失在6个月内会下降,而在有O3FA的情况下,其效果稳定且无减弱。这些结果表明了一种新的模式,即通过使用具有与受体结合药物的解离和组织消除相匹配的吸收动力学的可吸收生物相容性涂层材料,可以优化药物洗脱支架的安全性。